Brought to you by 
Abbott and Icagen in CNS and urological drug discovery deal
31 Aug 2020
Executive Summary
Abbott Laboratories and Icagen (ion channel drugs) have signed a three-year agreement to co-develop small-molecule drugs for central nervous system and urological disorders.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com